David Jorden
Vorstandsvorsitzender bei NUO THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.05.2024
Profil
David Emerson Jorden's current job(s) include being the CEO, CFO, Secretary & Director at Nuo Therapeutics, Inc. since 2016, and the Chief Executive Officer & Director at Nanospectra Biosciences, Inc. since 2013.
Mr. Jorden's former job(s) include being the Chief Financial Officer & Director at PLx Pharma, Inc., a Director at Opexa Therapeutics, Inc. from 2008 to 2013, a Vice President at Morgan Stanley from 2003 to 2008, a Principal at Fayez Sarofim & Co., and the Chief Financial Officer & Vice President at Genometrix, Inc. from 2000 to 2002.
Additionally, he served as the Chief Financial Officer at PLx Pharma, Inc. from 2015 to 2017.
Mr. Jorden's education history includes an undergraduate degree from The University of Texas at Austin in 1984 and an MBA from Kellogg School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUO THERAPEUTICS INC
4,46% | 15.03.2024 | 1 975 358 ( 4,46% ) | 1 Mio $ | 31.05.2024 |
Aktive Positionen von David Jorden
| Unternehmen | Position | Beginn |
|---|---|---|
| NUO THERAPEUTICS, INC. | Vorstandsvorsitzender | 08.01.2016 |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Vorstandsvorsitzender | 01.06.2013 |
Ehemalige bekannte Positionen von David Jorden
| Unternehmen | Position | Ende |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Finanzdirektor/CFO | 01.07.2017 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Finanzdirektor/CFO | 02.04.2013 |
| MORGAN STANLEY | Corporate Officer/Principal | - |
Genometrix, Inc.
 Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Finanzdirektor/CFO | 01.09.2002 |
Fayez Sarofim & Co.
 Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Corporate Officer/Principal | - |
Ausbildung von David Jorden
| The University of Texas at Austin | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MORGAN STANLEY | Finance |
| NUO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
PLx Pharma, Inc. /Old/
 PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Commercial Services |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
Fayez Sarofim & Co.
Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Finance |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
